All In Biotech

Drug Trial Radar · NCT07227415

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Nov 2, 2027

Study completion Nov 1, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Conditions

  • Carcinoma, Renal Cell
  • Advanced Renal Cell Carcinoma
  • Renal Cancer
  • Renal Neoplasm
  • Clear Cell Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Carcinoma, Renal Cell Metastasis
  • Advanced or Metastatic Renal Cell Carcinoma
  • Carcinoma, Renal Cell, Advanced
  • Metastatic Renal Cell Cancer
  • Metastatic Renal Cell Carcinoma ( mRCC)
  • Metastatic/Advanced Renal Cell Carcinoma

Interventions

  • PF-08634404Drug

    Concentrate for solution for infusion

  • IpilimumabDrug

    Solution for infusion

  • AxitinibDrug

    Tablet

  • CasdatifanDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigatorTime frame: Up to approximately 3 years
  2. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through 90 days after the last study intervention (Up to approximately 3 years)
  3. Number of participants with dose limiting toxicity (DLT)Time frame: Though end of DLT evaluation period (Up to approximately 3 years)

Locations

183 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Building- Phoenix

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • UCLA Hematology/Oncology - Alhambra

    Alhambra, California · Not yet recruiting

  • UCLA Hematology/Oncology - Atascadero

    Atascadero, California · Not yet recruiting

  • UCLA Hematology/Oncology - Burbank

    Burbank, California · Not yet recruiting

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • City of Hope Investigational Drug Services (IDS)

    Duarte, California · Recruiting

  • UC San Diego Medical Center - Encinitas

    Encinitas, California · Recruiting

  • UCLA Hematology/Oncology- Encino

    Encino, California · Not yet recruiting

  • UCLA Hematology/Oncology- Irvine

    Irvine, California · Not yet recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Investigational Drug Services (IDS)

    Irvine, California · Recruiting

  • UC San Diego / Moores Cancer Center

    La Jolla, California · Recruiting

  • UC San Diego Koman Family Outpatient Pavilion

    La Jolla, California · Recruiting

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California · Recruiting

  • UC San Diego Sulpizio Cardiovascular Center

    La Jolla, California · Recruiting

  • UCLA Hematology/Oncology - Laguna Hills

    Laguna Hills, California · Not yet recruiting

  • City of Hope

    Long Beach, California · Recruiting

  • Investigational Drug Services, Bowyer Pharmacy

    Los Angeles, California · Not yet recruiting

  • Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California · Not yet recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Not yet recruiting

  • UCLA Hematology/Oncology - Marina del Rey

    Marina del Rey, California · Not yet recruiting

  • UCLA Hematology/Oncology - Pasadena

    Pasadena, California · Not yet recruiting

  • UCLA Hematology/Oncology - Porter Ranch

    Porter Ranch, California · Not yet recruiting

  • UC San Diego Medical Center - Bankers Hill

    San Diego, California · Recruiting

  • UC San Diego McGrath Outpatient Pavilion - Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • UC San Diego Medical Center - Rancho Bernardo

    San Diego, California · Recruiting

  • UCLA Hematology/Oncology - San Luis Obispo

    San Luis Obispo, California · Not yet recruiting

  • UCLA Hematology/Oncology- Santa Barbara

    Santa Barbara, California · Not yet recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Not yet recruiting

  • UCLA Hematology/Oncology- Torrance

    Torrance, California · Not yet recruiting

  • City of Hope UPLAND

    Upland, California · Recruiting

  • UCLA Hematology/Oncology - Santa Clarita

    Valencia, California · Not yet recruiting

  • UCLA Hematology/Oncology- Ventura

    Ventura, California · Not yet recruiting

  • UC San Diego Medical Center - Vista

    Vista, California · Recruiting

  • UCLA Hematology/Oncology- Westlake

    Westlake Village, California · Not yet recruiting

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.